Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer

NCT07779538 | Not Yet Recruiting Phase 3

• 1 other identifier: SHR-A1811-321
• Study Type: interventional
• Target: 420
• Locations: 1 country
• Sites: 3

Brief Summary

This trial is a randomized, open-label, positive-controlled, multicenter phase Ib/III clinical trial, divided into two phases. Phase Ib aims to evaluate the safety and tolerability of SHR-A1811 in combination with bevacizumab as first-line maintenance therapy in participants with epithelial ovarian cancer without pathological progression (PD) after first-line platinum-based doublet chemotherapy plus bevacizumab (hereinafter referred to as "platinum-based triple therapy"). Phase III aims to evaluate the efficacy and safety of SHR-A1811 in combination with bevacizumab versus bevacizumab as maintenance therapy in participants with epithelial ovarian cancer without PD after first-line platinum-based triple therapy.

Conditions

Ovarian Cancer

Outcome Measures

Primary Outcomes (2)

• Dose limited toxicity (DLT)

  up to 21 days

• Progression Free Survival (PFS)

  the first 108 weeks, every 12 weeks, then every 24 weeks, lasting about 3 years

Secondary Outcomes (11)

• AEs+SAEs

  from the first drug administration to within 40 days for the last treatment dose

• Ctrough

  from the first drug administration to within 40 days for the last treatment dose

• ADA

  from the first drug administration to within 40 days for the last treatment dose

• Overall survival (OS)

  Approximately 3 years after last subject enrolled

• Second progression-free survival (PFS2)

  the first 108 weeks, every 12 weeks, then every 24 weeks, lasting about 3 years

Study Arms (2)

Treatment group A

EXPERIMENTAL

Drug: trastuzumab; Drug: bevacizumab

Treatment group B

OTHER

Drug: bevacizumab

Interventions

trastuzumab DRUG

trastuzumab

Treatment group A

bevacizumab DRUG

bevacizumab

Treatment group A; Treatment group B

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants voluntarily join this trial and sign an informed consent form.
• Newly diagnosed stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by histological or cytological pathology.
• Prior to first-line platinum-based doublet chemotherapy combined with bevacizumab.
• No disease progression as assessed by the investigator after completion of first-line platinum-based therapy and before randomization.
• Participants' homologous recombination deficiency test results must meet the criteria.
• Participants have not received any anti-tumor therapy from the last dose of first-line platinum-based therapy until randomization.
• Able to provide sufficient fresh or archived tumor tissue specimens for testing at the sponsor-designated central laboratory.
• ECOG PS score: 0-1.
• Expected survival ≥ 12 weeks.
• Laboratory tests within 7 days prior to randomization confirm that important organ function meets the requirements.
• Female participants of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) test within 7 days prior to randomization and must not be breastfeeding; female participants of childbearing potential must agree to adhere to contraception from the date of signing the informed consent form until 7 months after the last dose.

You may not qualify if:

• Participants with untreated or active central nervous system (CNS) metastases; a history of meningeal metastases or current meningeal metastases.
• Participants with clinically symptomatic, poorly controlled, or moderate to severe pleural effusion, pericardial effusion, or ascites.
• Participants with a history of or concurrent other malignancies, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary thyroid carcinoma, and other malignancies that have been adequately treated and cured for ≥5 years prior to randomization with evidence of no recurrence or metastasis.
• Participants with a history of interstitial pneumonia/interstitial lung disease requiring steroid treatment, non-infectious pneumonia (such as radiation pneumonitis), current or suspected interstitial pneumonia/interstitial lung disease, non-infectious pneumonia, or other active pneumonia; or those with severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, or other lung damage within 6 months prior to randomization.
• \. Individuals with active pulmonary tuberculosis; those who have received adequate and regular treatment and have stopped anti-tuberculosis treatment for ≥3 months prior to randomization are eligible for enrollment.
• \. Individuals with poorly controlled or severe cardiovascular disease. 8. Individuals who have experienced arterial/venous thrombotic events within 6 months prior to randomization.
• \. Individuals who have experienced NCI-CTCAE v6.0 grade ≥2 bleeding events within 1 month prior to randomization.
• \. Individuals with known hereditary or acquired bleeding (e.g., coagulation disorders) or thrombotic tendency.
• \. Individuals who have experienced or are expected to experience gastrointestinal perforation or fistula, tracheal fistula, urethral fistula, or abdominal abscess in the near future.
• \. Individuals with gastrointestinal obstruction or symptoms and signs of gastrointestinal obstruction within 3 months prior to randomization; individuals who have previously undergone intestinal stent implantation and whose intestinal stent has not been removed by the screening period.
• \. Participants who have experienced severe infection within 1 month prior to randomization.
• \. Participants who have tested positive for human immunodeficiency virus (HIV); participants with known active hepatitis.
• \. Participants who have undergone major surgery within 4 weeks prior to randomization or whose surgical side effects have not recovered or stabilized prior to randomization. 16. Patients who may receive other systemic anti-tumor therapies during treatment or are scheduled for further debulking surgery.
• \. Patients whose toxicity from previous anti-tumor therapy has not recovered to grade ≤1 according to the NCI-CTCAE v6.0 classification.
• \. Patients with known hypersensitivity to any component of the SHR-A1811 product or other monoclonal antibody drugs.

Sponsors & Collaborators

• Suzhou Suncadia Biopharmaceuticals Co., Ltd.: lead

Study Sites (3)

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100020, China

Location

Zhejiang Cancer Hospital

Zhejiang, Hangzhou, China

Location

Yunnan Cancer Hospital

Yunnan, Kunming, 650118, China

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

Trastuzumab; Bevacizumab

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Central Study Contacts

Shuni Wang, M.D

CONTACT

+86-0518-81220121; shuni.wang@hengrui.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 14, 2026
• First Posted: August 21, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): February 28, 2030
• Study Completion (Estimated): May 30, 2030
• Last Updated: August 21, 2026

Record last verified: 2026-07

Locations

CN (3)